Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.3 USD | +1.19% | +0.61% | -8.91% |
23/05 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
23/05 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.91% | 142.88Cr | |
+17.38% | 7.98TCr | |
+11.81% | 911.93Cr | |
+42.52% | 446.15Cr | |
-22.31% | 442.21Cr | |
+10.76% | 412.79Cr | |
+6.58% | 218.28Cr | |
-27.16% | 216.56Cr | |
+11.24% | 201.28Cr | |
-43.24% | 177.35Cr |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing